Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eric Gale
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Reveal Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Gale owns private equity in the above mentioned interest that is specialized in developing contrasts for magnetic resonance imaging (MRI). This grant will use and develop a new MRI contrast that is manganese based, an alternative to MRI contrasts that contain Gadolinium. Not only is the above mentioned company in the same field of study, the IP resulting from research under this grant will be licensed to the company. Based on the magnitude of this financial interest and the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
A Manganese Alternative to Gadolinium for MRI
Narrative Kidney disease patients are adversely impacted by toxicity concerns associated with contrast media routinely administered in CT and MRI examinations, which can preclude important radiologic examinations. 14% of US adults suffer from chronic kidney disease and contrast that is compatible with this patient group is sorely needed. The goal of this application is to develop new, manganese-based MRI contrast media designed for kidney disease compatibility.
Filed on December 06, 2016.
Tell us what you know about Eric Gale's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Eric Gale filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Eric Gale | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.